ViroBlock, a Hebrew University of Jerusalem Company, Announces Progress on Novel Platform Yielding New Drug That Could Treat Current and Future COVID-19 Variants; Similar Efforts Show Promise against Influenza, Zika, West Nile, Hepatitis, and Future Viral Threats